Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions

Clinical Cancer Research

Volumn 13, Issue 19, 2007, Pages 5805-5809

  Salani, Ritu ^a   Davidson, Ben ^b   Fiegl, Michael ^c   Marth, Christian ^d   Müller Holzner, Elisabeth ^d   Gastl, Guenther ^c   Huang, Han Yao ^a   Hsiao, Jui Chi ^e   Lin, Her Sheng ^e   Wang, Tian Li ^a   Lin, Bai Ling ^e   Shih, Ie Ming ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CYCLIN E; DNA FRAGMENT; GENOMIC DNA; PROTEIN P53;

ARTICLE; CHROMOSOME 2P; CHROMOSOME 4P; CYTOLOGY; DNA ISOLATION; FEMALE; GENE AMPLIFICATION; GENE LOCUS; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

AREA UNDER CURVE; CARCINOMA; CELL-FREE SYSTEM; CHROMOSOME MAPPING; CYCLIN E; DNA; DNA PRIMERS; FALSE NEGATIVE REACTIONS; GENOME; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 35348906194     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0853     Document Type: Article

References (29)

1. Diamandis EP. Tumor markers: past, present and future. In: Diamandis EP, editor. Tumor markers, 1st ed. Washington (DC): American Association for Clinical Chemistry; 2002. p. 3-8.
2. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50.
3. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999;18:65-73.
4. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
5. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
6. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005;102:16368-73.
7. Chang HW, Ali SZ, Cho SK, Kurman RJ, Shih I-M. Detection of allelic imbalance in ascitic supernatant by digital single nucleotide polymorphism analysis. Clin Cancer Res 2002;8:2580-5.
8. Chang HW, Lee SM, Goodman SN, et al. Assessment of plasma DNA levels, allelic imbalance, and CA125 as diagnostic tests for cancer. J Natl Cancer Inst 2002;94:1697-703.
9. Muller M, Krause H, Goessl C. Circulating cancer cells and cell-free nucleic acids as tumor markers. In: Diamandis EP, Fritsche H, Lilja H, Chan CCW, Schwartz MK, editors. Tumor markers, 1st ed. Washington (DC): American Association for Clinical Chemistry; 2002. p.107-22.
10. Huang ZH, Li L, Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett 2006.
11. Allen D, Butt A, Cahill D, et al. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann N Y Acad Sci 2004;1022:76-80.
12. Herrera LJ, Raja S, Gooding WE, et al. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 2005;51:113-8.
13. Taback B, Fujiwara Y, Wang HJ, et al. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res 2001;61:5723-6.
14. Taback B, O'Day SJ, Hoon DS. Quantification of circulating DNA in the plasma and serum of cancer patients. Ann N Y Acad Sci 2004;1022:17-24.
15. Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res 2003;63:3966-8.
16. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003;49:1058-65.
17. Kinzler KW, Vogelstein B. The genetic basis of human cancer. 2nd ed. Toronto: McGraw-Hill; 2002.
18. Parrella P, Zangen R, Sidransky D, Nicol T. Molecular analysis of peritoneal fluid in ovarian cancer patients. Mod Pathol 2003;16:636-40.
19. Nakayama K, Nakayama N, Jinawath N, et al. Amplicon profiles in ovarian serous carcinomas. Int J Cancer 2007;120:2613-7.
20. Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 2003;97:389-404.
21. Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat 2003;21:285-91.
22. Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF. Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res 1993;53:2631-43.
23. Garrison RN, Galloway RH, Heuser LS. Mechanisms of malignant ascites production. J Surg Res 1987;42:126-32.
24. Davidson B. Malignant effusions: from diagnosis to biology. Diagn Cytopathol 2004;31:246-54.
25. Davidson B, Risberg B, Reich R, Berner A. Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. Clin Lab Med 2003;23:729-54, viii.
26. Fiegl M, Haun M, Massoner A, et al. Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse-transcriptase polymerase chain reaction for human mammaglobin/mammaglobin B expression improves diagnosis of malignant effusions. J Clin Oncol 2004;22:474-83.
27. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004;2:257-80.
28. Shih I-M. Application of HLA-G expression in the diagnosis of human cancer. Hum Immunol 2007;68:272-6.
29. Shih I-M, Salani R, Fiegl M, et al. Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol 2007;105:501-7.